-
About US
About US
- Patients
-
Professional Medical Solutions
Professional Medical Solutions
- News
- Investor Relations
A Leading Global Innovative Medical Technology Enterprise focusing on the R&D and application of technology platforms in vascular interventional treatment. Relying on four unique technology platforms of drug-coating technology, RF ablation technology, polymer material technology, and aspiration platform technology, Acotec stays the course of reliable innovative ideas to continuously exploit unmet clinical needs, which provides brand-new treatment methods and reliable products for both doctors and patients.
With its diversified product portfolio, Acotec will continuously sustain innovation in vascular intervention treatment to struggle against vascular diseases. On the way of becoming one of the global leaders among medical technology enterprises, Acotect helps patients achieve long-term clinical benefits and improve their life quality by constantly bringing high-quality systemic vascular interventional treatment solutions to doctors and patients worldwide.
Always be committed to achieving long-term clinical benefits and improving the life quality of patients
Struggle against vascular diseases and become one of the global leaders among medical technology enterprises
Reliable innovative medical technology platforms
Bring new treatment methods and reliable products to doctors and patients and improve the holistic level of vascular disease treatment so that more patients with vascular diseases can return to a healthy life with high-quality
Make constant innovation: Adhere to reliable innovative ideas with our imaginative mind to continuously provide new treatment methods and reliable products and open up the next frontier of vascular interventional treatment
Aim at long-term clinical benefits, respect facts and evidence, and explore unmet clinical needs to offer more possible solutions for treating vascular diseases
· The complete set of RF ablation equipment was approved for market
· The expansion of DCB used for AVF of hemodialysis patients was approved by NMPA
· The percutaneous support catheter (Vericor) was approved by NMPA for market
· The intracranial balloon dilatation catheter (NEO-Skater) was approved by NMPA for market
· The PTA catheter (P-Conic) was approved by NMPA for market
· The coronary artery balloon dilatation catheter (YAN) was approved by NMPA for market
· Our products have been commercialized in 13 countries across the world
· The company was listed in HKEX
· The complete set of equipment of percutaneous vascular aspiration system was approved by NMPA for market
· AcoArt Tulip® & Litos® (the world's first clinically proven below-the-knee DCB) was approved by NMPA for market
· The company acquired Shenzhen Vascupatent to establish the Shenzhen Polymer Material R&D Center
· AcoArt Tulip® & Litos® (below-the-knee DCB) were granted the "Breakthrough Device Designation" by FDA
· AcoArt Orchid® & Dhalia® (above-the-knee DCB) were approved by NMPA for market
· PTA was approved by NMPA for market
· The products of DCB and PTA was passed the CE certification and launched in Europe
· The company was nominated as the "Core Enterprise" of the Beijing Economic-technological Development Area
· DCB was included in the National Key Technology Research and Development Program during the 12th Five-Year Plan
· Beijing Acotec was founded
· Initiate R&D of the percutaneous transluminal angioplasty (PTA) catheter and the drug-coated balloon (DCB)
· The complete set of RF ablation equipment was approved for market
· The expansion of DCB used for AVF of hemodialysis patients was approved by NMPA
· The percutaneous support catheter (Vericor) was approved by NMPA for market
· The intracranial balloon dilatation catheter (NEO-Skater) was approved by NMPA for market
· The PTA catheter (P-Conic) was approved by NMPA for market
· The coronary artery balloon dilatation catheter (YAN) was approved by NMPA for market
· Our products have been commercialized in 13 countries across the world
· The company was listed in HKEX
· The complete set of equipment of percutaneous vascular aspiration system was approved by NMPA for market
· AcoArt Tulip® & Litos® (the world's first clinically proven below-the-knee DCB) was approved by NMPA for market
· The company acquired Shenzhen Vascupatent to establish the Shenzhen Polymer Material R&D Center
· AcoArt Tulip® & Litos® (below-the-knee DCB) were granted the "Breakthrough Device Designation" by FDA
· AcoArt Orchid® & Dhalia® (above-the-knee DCB) were approved by NMPA for market
· PTA was approved by NMPA for market
· The products of DCB and PTA was passed the CE certification and launched in Europe
· The company was nominated as the "Core Enterprise" of the Beijing Economic-technological Development Area
· DCB was included in the National Key Technology Research and Development Program during the 12th Five-Year Plan
· Beijing Acotec was founded
· Initiate R&D of the percutaneous transluminal angioplasty (PTA) catheter and the drug-coated balloon (DCB)
Shanghai Office
Room 603, T1, IMShanghai, Line 1388, Kaixuan Road, Changning District, Shanghai
Beijing Headquarters
4-5/F., Building 1, No. 16, North Hongda Road, Beijing Economic-technological Development Area, Beijing, PRC
Tel：010-67872107
Fax：010-67866678
Room 2705, R&F Goodrich Building, No. 3, Huaqiang Road, Tianhe District, Guangzhou City, Guangdong Province
Room 314 & Room 316, Building A, Life Science Park Branch 3, No. 22, East Jinxiu Road, Jinsha Community, Kengzi Subdistrict, Pingshan District, Shenzhen
Tel：0755-89663013
Way of Compliance Reporting：compliance@acotec.cn
Copyright © 2023 先瑞达医疗科技控股有限公司 京ICP备19054161号-2 MINETHINK